Abstract

Despite the continuous improvement of various therapeutic techniques, the overall prognosis of tumors has been significantly improved, but malignant tumors in the middle and advanced stages still cannot be completely cured. It is now evident that cell adhesion-mediated resistance (CAM-DR) limits the success of cancer therapies and is a great obstacle to overcome in the clinic. The interactions between tumor cells and extracellular matrix (ECM) molecules or adjacent cells may play a significant role in initiating the intracellular signaling pathways that are associated with cell proliferation, survival upon binding to their ligands. Recent studies illustrate that these adhesion-related factors may contribute to the survival of cancer cells after chemotherapeutic therapy, advantageous to resistant cells to proliferate and develop multiple mechanisms of drug resistance. In this review, we focus on the molecular basis of these interactions and the main signal transduction pathways that are involved in the enhancement of the cancer cells’ survival. Furthermore, therapies targeting interactions between cancer cells and their environment to enhance drug response or prevent the emergence of drug resistance will also be discussed.

Highlights

  • Chemotherapy remains the major treatment of disseminated cancer including hematologic malignancies and metastatic solid tumors

  • In bone-metastatic castration-resistant prostate cancer (CRPC), the interaction between tumor cells and microenvironment combined with hypoxia can lead to the continuous activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway, which eventually leads to drug resistance

  • In the continuous improvement of tumor clinical treatment, drug resistance has become a non-negligible hotspot, which is a key factor for successful treatment

Read more

Summary

Introduction

Chemotherapy remains the major treatment of disseminated cancer including hematologic malignancies and metastatic solid tumors. Existing studies have shown that the interaction of myeloma cells and tumor microenvironment plays an important role in the treatment of drug resistance, especially CAM-DR (Di Marzo et al, 2016; Ullah, 2019). The expression of some molecules can reduce the proliferation of tumor cells, the production of CAM-DR is consistent with the clinical practice that is not sensitive to the treatment of inert lymphomas, such as DYRK2 (Wang et al, 2015).

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.